Earnings Feed
Sign Up
Home/Filings/4/0001209191-17-032205
4//SEC Filing

Revance Therapeutics, Inc. 4

Accession 0001209191-17-032205

CIK 0001479290operating
View on SEC.govCompany Profile

Filed

May 11, 8:00 PM ET

Accepted

May 12, 7:47 PM ET

Size

10.6 KB

Accession

0001209191-17-032205

Insider Transaction Report

Form 4
Period: 2017-05-11
Revance Therapeutics, Inc.RVNC
Eastman Ronald W
Director10% Owner
Transactions
  • Award

    Common Stock

    2017-05-11+3,000→ 3,000 total
  • Award

    Stock Option (Right to Buy)

    2017-05-11+6,000→ 6,000 total
    Exercise: $20.90Exp: 2027-05-10→ Common Stock (6,000 underlying)
Holdings

  • Common Stock

    (indirect: By Essex Woodlands Health Ventures Fund VIII, L.P)
    3,747,332

  • Common Stock

    (indirect: By Essex Woodlands Health Ventures Fund VIII-A, L.P.)
    270,172

  • Common Stock

    (indirect: By Essex Woodlands Health Ventures Fund VIII-B, L.P.)
    117,458
Footnotes (5)
  • [F1]Represents an annual restricted stock award (the "RSA") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on the one year anniversary, May 11, 2018, subject to Mr. Eastman's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan (the "Plan")) through such vesting date.
  • [F2]The voting and dispositive decisions with respect to the shares held by Essex Woodlands Health Ventures Fund VIII, L.P. are made by its general partner, Essex Woodland Health Ventures VIII, LLC and one of Issuer's directors, Ronald W Eastman.
  • [F3]The voting and dispositive decisions with respect to the shares held by Essex Woodlands Health Ventures Fund VIII-A, L.P. are made by its general partner, Essex Woodland Health Ventures VIII, LLC and one of Issuer's directors, Ronald W Eastman.
  • [F4]The voting and dispositive decisions with respect to the shares held by Essex Woodlands Health Ventures Fund VIII-B, L.P. are made by its general partner, Essex Woodland Health Ventures VIII, LLC and one of Issuer's directors, Ronald W Eastman.
  • [F5]The shares subject to the stock option shall vest on the one year anniversary, May 11, 2018, subject to Mr. Eastman's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual option grant pursuant to the Compensation Policy.

Documents

1 file

Issuer

Revance Therapeutics, Inc.

CIK 0001479290

→
Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001479290

Filing Metadata

Form type
4
Filed
May 11, 8:00 PM ET
Accepted
May 12, 7:47 PM ET
Size
10.6 KB
View on SEC.gov